Lucentis ranibizumab regulatory update

FDA approved an sBLA from Roche’s Genentech unit for Lucentis ranibizumab to treat diabetic retinopathy in patients with diabetic macular edema (DME). The humanized mAb fragment against VEGF-A is app...